BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
ECCV
Eagle Point Credit Company Inc.
There isn't enough reported data to score ECCV yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
ECCV Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| N/A | |
| N/A |
ECCV's revenue and profitability are currently weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like ECCV.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
ECCV PE Valuation
ECCV has no meaningful PE right now: it lost money over the past year.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
ECCV Forward outlook
There aren't enough analyst estimates for ECCV to show an outlook.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over ECCV on earnings quality, reporting a profit while its opponent remains loss making.
ECCV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.24 | -1227% |
| Q1 2026 | -$1.29 | -$0.89 |
| Q4 2025 | -$0.98 | -217% |
| Q3 2025 | $0.26 | -67% |
| Q2 2025 | $0.11 | -93% |
| Q1 2025 | -$0.40 | -123% |
| Q4 2024 | $0.84 | -50% |
| Q3 2024 | $0.78 | -48% |
ECCV has swung to a loss: it lost $1.24 per share over the past year, after a profit the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over ECCV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
ECCV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $31.4M | -45% |
| Q3 2025 | $52M | +10% |
| Q1 2025 | $57.7M | +41% |
| Q4 2024 | $49.5M | +26% |
| Q3 2024 | $47.1M | +31% |
| Q1 2024 | $40.8M | +32% |
| Q4 2023 | $39.4M | +21% |
| Q3 2023 | $36M | +19% |
ECCV's revenue has slid since its 2025 peak: −$63M last quarter, down 188% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -433% | -282 points |
| Q3 2025 | 75% | +1.5 points |
| Q2 2025 | 87% | N/A |
| Q1 2025 | -152% | -220 points |
| Q4 2024 | 65% | -7.4 points |
| Q3 2024 | 73% | +0.9 points |
| Q1 2024 | 69% | -9 points |
| Q4 2023 | 73% | -2.6 points |
ECCV's operating margin was −433% last quarter, down 498 points from the same quarter a year ago, near the bottom of its range since 2019.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
ECCV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $34.8M | +17% |
| Q1 2026 | $29M | +6% |
| Q4 2025 | $30.3M | +24% |
| Q3 2025 | -$16.3M | -158% |
| Q2 2025 | $29.7M | +3.2% |
| Q1 2025 | $27.4M | +24% |
| Q4 2024 | $24.5M | +2% |
| Q3 2024 | $28.2M | +27% |
ECCV has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over ECCV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
ECCV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +480K shares |
| 1 year | +11% | +12.8M shares |
| 3 years | +112% | +70.2M shares |
| 5 years | +286% | +98.5M shares |
| Available history | +390% | +106M shares |
ECCV has 133M diluted shares, up 11% from a year ago, despite $63M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q2 2026 | $57.9M |
| Q1 2026 | $4.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ECCV spent $63M buying back its own shares over the past year, after none the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
ECCV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 7.6x | High |
| Q2 2025 | 4.8x | High |
| Q1 2024 | 1.8x | Healthy |
| Q4 2023 | 1.1x | Healthy |
| Q3 2023 | 1.8x | Healthy |
| Q2 2023 | 1.2x | Healthy |
| Q1 2023 | 2.1x | Moderate |
| Q4 2022 | 1.1x | Healthy |
ECCV's net debt is about 7.6 years of its operating earnings (EBITDA), up from 1.8 years a year ago. Net leverage isn't a meaningful measure for financial services companies like ECCV.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
ECCV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.4 | Neutral |
| Stochastic | 43.3 | Neutral |
ECCV's weekly RSI is 52 (neutral) and its Stochastic is 43 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
ECCV PE vs Financial Services Sector
| Metric | ECCV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
ECCV has no meaningful PE right now: it lost money over the past year.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
ECCV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $24.2 | 0.1% below |
| 20 week MA | $24.1 | 0.2% above |
| 50 week MA | $23.9 | 1.1% above |
| 100 week MA | $23.5 | 2.8% above |
| 200 week MA | $22.9 | 5.6% above |
ECCV has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
ECCV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $24.3 | $21.0 | -13% |
| 2023 | $21.0 | $22.4 | +6.4% |
| 2024 | $22.4 | $22.7 | +1.6% |
| 2025 | $22.7 | $23.5 | +3.5% |
| 2026 YTD | $23.5 | $24.2 | +2.8% |
ECCV has the edge over BAC on returns for 2026, with the stronger performance.